FIGURE 5.
Proposed design for clinical DDI studies with alternative CYP3A inducers (a) carbamazepine; (b) phenytoin and lumacaftor with CYP3A substrates. PK, pharmacokinetic.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.